🇺🇸 FDA
Patent

US 11613744

Modified urokinase-type plasminogen activator polypeptides and methods of use

granted A61KA61K38/00

Quick answer

US patent 11613744 (Modified urokinase-type plasminogen activator polypeptides and methods of use) held by Vertex Pharmaceuticals Incorporated expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
77
CPC classes
A61K, A61K38/00